{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:27:41Z","timestamp":1794360461199,"version":"4.9.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004270","name":"Royal Institute of Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004270","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Muscle"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Becker muscular dystrophy (BMD) is a rare and heterogeneous form of dystrophinopathy caused by expression of altered dystrophin proteins, as a consequence of in-frame genetic mutations. The majority of the BMD biomarker studies employ targeted approaches and focus on translating findings from Duchenne Muscular Dystrophy (DMD), a more severe disease form with clinical similarities but caused by out-of-frame mutations in the dystrophin gene. Importantly, DMD therapies assume that disease progression can be slowed by promoting the expression of truncated dystrophin comparable to what occurs in BMD patients. In this study, we explore similarities and differences in protein trajectories over time between BMD and DMD serum, and explore proteins related to motor function performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum samples collected from 34 BMD patients, in a prospective longitudinal 3-year study, and 19 DMD patients, were analyzed by using Data Independent Acquisition Tandem Mass Spectrometry (DIA-MS). Subsequent normalization, linear mixed effects model was employed to identify proteins associated with physical tests and dystrophin expression in skeletal muscle. Analysis was also performed to explore the discrepancy between DMD and BMD biomarker abundance trajectories over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Linear mixed effects models identified 20 proteins with altered longitudinal signatures between DMD and BMD, including creatine kinase M-type (CKM) pyruvate kinase (PKM), fibrinogen gamma chain (FGG), lactate dehydrogenase B (LDHB) and alpha-2-macroglobulin (A2M). Furthermore, several proteins related to innate immune response were associated with motor function in BMD patients. In particular, A2M displayed an altered time-dependent decline in relation to dystrophin expression in the tibialis anterior muscle.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study revealed differences in the serum proteome between BMD and DMD, which comprises proteins involved in the immune response, extracellular matrix organization and hemostasis but not muscle leakage proteins significantly associated with disease progression in DMD. If further evaluated and validated, these biomarker candidates may offer means to monitor disease progression in BMD patients. A2M is of particular interest due to its association with dystrophin expression in BMD muscle and higher abundance in DMD patients in comparison to BMD. If validated, A2M could be used as a pharmacodynamic biomarker in therapeutic clinical trials aiming to restore dystrophin expression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13395-025-00385-3","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T23:21:28Z","timestamp":1749252088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Contrasting Becker and Duchenne muscular dystrophy serum biomarker candidates by using data independent acquisition LC-MS\/MS"],"prefix":"10.1186","volume":"15","author":[{"given":"Camilla","family":"Johansson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther J.","family":"Schrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kotol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Za\u00efda","family":"Koeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke M.","family":"van de Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J. G. M.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik H.","family":"Niks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Edfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Spitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Al-Khalili Szigyarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"issue":"7","key":"385_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.15252\/emmm.201303724","volume":"6","author":"B Ayoglu","year":"2014","unstructured":"Ayoglu B, et al. Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies. EMBO Mol Med. 2014;6(7):918\u201336.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"385_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/JND-190454","volume":"7","author":"K Strandberg","year":"2020","unstructured":"Strandberg K, et al. Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy. J Neuromuscul Dis. 2020;7(3):231\u201346.","journal-title":"J Neuromuscul Dis"},{"key":"385_CR3","doi-asserted-by":"publisher","first-page":"17014","DOI":"10.1038\/srep17014","volume":"5","author":"AM Coenen-Stass","year":"2015","unstructured":"Coenen-Stass AM, et al. Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics. Sci Rep. 2015;5:17014.","journal-title":"Sci Rep"},{"key":"385_CR4","doi-asserted-by":"crossref","unstructured":"Grounds MD et al. Biomarkers for Duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress. Dis Model Mech. 2020;13(2):dmm043638.","DOI":"10.1242\/dmm.043638"},{"key":"385_CR5","doi-asserted-by":"publisher","first-page":"43697","DOI":"10.1038\/srep43697","volume":"7","author":"S Guiraud","year":"2017","unstructured":"Guiraud S, et al. Identification of serum protein biomarkers for utrophin based DMD therapy. Sci Rep. 2017;7:43697.","journal-title":"Sci Rep"},{"issue":"23","key":"385_CR6","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1073\/pnas.1507719112","volume":"112","author":"Y Hathout","year":"2015","unstructured":"Hathout Y, et al. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A. 2015;112(23):7153\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"385_CR7","doi-asserted-by":"publisher","first-page":"678974","DOI":"10.3389\/fphys.2021.678974","volume":"12","author":"R Rossi","year":"2021","unstructured":"Rossi R, et al. Circadian genes as exploratory biomarkers in DMD: results from both the Mdx mouse model and patients. Front Physiol. 2021;12:678974.","journal-title":"Front Physiol"},{"issue":"2","key":"385_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/jcsm.12517","volume":"11","author":"M Signorelli","year":"2020","unstructured":"Signorelli M, et al. Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle. 2020;11(2):505\u201317.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"385_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13018-022-02996-8","volume":"17","author":"N Salari","year":"2022","unstructured":"Salari N, et al. Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis. J Orthop Surg Res. 2022;17(1):96.","journal-title":"J Orthop Surg Res"},{"issue":"7","key":"385_CR10","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1177\/0192623317734823","volume":"45","author":"K Wilson","year":"2017","unstructured":"Wilson K, et al. Duchenne and Becker muscular dystrophies: A review of animal models, clinical end points, and biomarker quantification. Toxicol Pathol. 2017;45(7):961\u201376.","journal-title":"Toxicol Pathol"},{"issue":"4","key":"385_CR11","first-page":"179","volume":"39","author":"EP Hoffman","year":"2020","unstructured":"Hoffman EP. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies. Acta Myol. 2020;39(4):179\u201386.","journal-title":"Acta Myol"},{"issue":"2","key":"385_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/ana.25951","volume":"89","author":"Y de Feraudy","year":"2021","unstructured":"de Feraudy Y, et al. Very low residual dystrophin quantity is associated with milder dystrophinopathy. Ann Neurol. 2021;89(2):280\u201392.","journal-title":"Ann Neurol"},{"issue":"9\u201310","key":"385_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1089\/hum.2022.190","volume":"34","author":"JS Chamberlain","year":"2023","unstructured":"Chamberlain JS, et al. Microdystrophin expression as a surrogate endpoint for Duchenne muscular dystrophy clinical trials. Hum Gene Ther. 2023;34(9\u201310):404\u201315.","journal-title":"Hum Gene Ther"},{"issue":"1","key":"385_CR14","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.1038\/s41598-021-84863-w","volume":"11","author":"Z Koeks","year":"2021","unstructured":"Koeks Z, et al. Low dystrophin variability between muscles and stable expression over time in Becker muscular dystrophy using capillary Western immunoassay. Sci Rep. 2021;11(1):5952.","journal-title":"Sci Rep"},{"issue":"8","key":"385_CR15","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.nmd.2019.06.004","volume":"29","author":"IEC Verhaart","year":"2019","unstructured":"Verhaart IEC, et al. Muscle biopsies in clinical trials for Duchenne muscular dystrophy\u2013 Patients\u2019 and caregivers\u2019 perspective. Neuromuscul Disord. 2019;29(8):576\u201384.","journal-title":"Neuromuscul Disord"},{"key":"385_CR16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.omtm.2020.06.016","volume":"18","author":"V Mariot","year":"2020","unstructured":"Mariot V, et al. Myostatin is a quantifiable biomarker for monitoring Pharmaco-gene therapy in Duchenne muscular dystrophy. Mol Ther Methods Clin Dev. 2020;18:415\u201321.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"385_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3233\/JND-221513","volume":"11","author":"G Ricci","year":"2024","unstructured":"Ricci G, et al. Characterization of phenotypic variability in Becker muscular dystrophy for clinical practice and towards trial readiness: A Two-Years follow up study. J Neuromuscul Dis. 2024;11(2):375\u201387.","journal-title":"J Neuromuscul Dis"},{"issue":"7","key":"385_CR18","doi-asserted-by":"publisher","first-page":"e16282","DOI":"10.1111\/ene.16282","volume":"31","author":"B De Wel","year":"2024","unstructured":"De Wel B, et al. Lessons for future clinical trials in adults with Becker muscular dystrophy: disease progression detected by muscle magnetic resonance imaging, clinical and patient-reported outcome measures. Eur J Neurol. 2024;31(7):e16282.","journal-title":"Eur J Neurol"},{"issue":"9","key":"385_CR19","doi-asserted-by":"crossref","first-page":"e975","DOI":"10.1212\/WNL.0000000000201609","volume":"100","author":"NM van de Velde","year":"2023","unstructured":"van de Velde NM, et al. Longitudinal assessment of creatine kinase, creatine\/Creatinine(ratio), and myostatin as monitoring biomarkers in Becker muscular dystrophy. Neurology. 2023;100(9):e975\u201384.","journal-title":"Neurology"},{"issue":"3","key":"385_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2144\/btn-2021-0047","volume":"71","author":"D Kotol","year":"2021","unstructured":"Kotol D, et al. Targeted proteomics analysis of plasma proteins using Recombinant protein standards for addition only workflows. Biotechniques. 2021;71(3):473\u201383.","journal-title":"Biotechniques"},{"issue":"12","key":"385_CR21","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.1021\/acs.jproteome.0c00194","volume":"19","author":"D Kotol","year":"2020","unstructured":"Kotol D, et al. Longitudinal plasma protein profiling using targeted proteomics and Recombinant protein standards. J Proteome Res. 2020;19(12):4815\u201325.","journal-title":"J Proteome Res"},{"issue":"10","key":"385_CR22","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/nbt.2377","volume":"30","author":"MC Chambers","year":"2012","unstructured":"Chambers MC, et al. A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol. 2012;30(10):918\u201320.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"385_CR23","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1038\/s41467-018-07454-w","volume":"9","author":"BC Searle","year":"2018","unstructured":"Searle BC, et al. Chromatogram libraries improve peptide detection and quantification by data independent acquisition mass spectrometry. Nat Commun. 2018;9(1):5128.","journal-title":"Nat Commun"},{"issue":"6","key":"385_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41592-019-0426-7","volume":"16","author":"S Gessulat","year":"2019","unstructured":"Gessulat S, et al. Prosit: proteome-wide prediction of peptide tandem mass spectra by deep learning. Nat Methods. 2019;16(6):509\u201318.","journal-title":"Nat Methods"},{"issue":"7","key":"385_CR25","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/bioinformatics\/btq054","volume":"26","author":"B MacLean","year":"2010","unstructured":"MacLean B, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010;26(7):966\u20138.","journal-title":"Bioinformatics"},{"issue":"08","key":"385_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4236\/abb.2018.98022","volume":"9","author":"JE Wulff","year":"2018","unstructured":"Wulff JE, Mitchell MW. A comparison of various normalization methods for LC\/MS metabolomics data. Adv Bioscience Biotechnol. 2018;9(08):339\u201351.","journal-title":"Adv Bioscience Biotechnol"},{"key":"385_CR27","unstructured":"R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URLhttps:\/\/www.R-project.org\/"},{"issue":"1","key":"385_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, et al. Fitting linear Mixed-Effects models using lme4. J Stat Softw. 2015;67(1):1\u201348.","journal-title":"J Stat Softw"},{"issue":"1","key":"385_CR29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery Rate - a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B-Statistical Methodol. 1995;57(1):289\u2013300.","journal-title":"J Royal Stat Soc Ser B-Statistical Methodol"},{"issue":"1","key":"385_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1074\/mcp.RA119.001714","volume":"19","author":"K Barkovits","year":"2020","unstructured":"Barkovits K, et al. Reproducibility, specificity and accuracy of relative quantification using spectral Library-based Data-independent acquisition. Mol Cell Proteom. 2020;19(1):181\u201397.","journal-title":"Mol Cell Proteom"},{"issue":"13","key":"385_CR31","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1021\/ac051632c","volume":"78","author":"F Dieterle","year":"2006","unstructured":"Dieterle F, et al. Probabilistic quotient normalization as robust method to account for Dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem. 2006;78(13):4281\u201390.","journal-title":"Anal Chem"},{"issue":"1","key":"385_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12014-023-09412-1","volume":"20","author":"C Johansson","year":"2023","unstructured":"Johansson C, et al. Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers. Clin Proteom. 2023;20(1):23.","journal-title":"Clin Proteom"},{"issue":"1","key":"385_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/mus.27222","volume":"64","author":"BL Barthel","year":"2021","unstructured":"Barthel BL, et al. Elevation of fast but not slow troponin I in the circulation of patients with Becker and Duchenne muscular dystrophy. Muscle Nerve. 2021;64(1):43\u20139.","journal-title":"Muscle Nerve"},{"issue":"4","key":"385_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/jcsm.12304","volume":"9","author":"P Spitali","year":"2018","unstructured":"Spitali P, et al. Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies. J Cachexia Sarcopenia Muscle. 2018;9(4):715\u201326.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"15","key":"385_CR35","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2217\/bmm-2021-0222","volume":"15","author":"KR Wagner","year":"2021","unstructured":"Wagner KR, et al. Safety and disease monitoring biomarkers in Duchenne muscular dystrophy: results from a phase II trial. Biomark Med. 2021;15(15):1389\u201396.","journal-title":"Biomark Med"},{"issue":"2","key":"385_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/jcsm.12527","volume":"11","author":"D Capitanio","year":"2020","unstructured":"Capitanio D, et al. Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients. J Cachexia Sarcopenia Muscle. 2020;11(2):547\u201363.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"385_CR37","doi-asserted-by":"publisher","first-page":"803244","DOI":"10.3389\/fimmu.2021.803244","volume":"12","author":"J Vandooren","year":"2021","unstructured":"Vandooren J, Itoh Y. Alpha-2-Macroglobulin in inflammation, immunity and infections. Front Immunol. 2021;12:803244.","journal-title":"Front Immunol"},{"issue":"4","key":"385_CR38","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/jth.15647","volume":"20","author":"J Lagrange","year":"2022","unstructured":"Lagrange J, et al. Alpha-2\u2010macroglobulin in hemostasis and thrombosis: an underestimated old double\u2010edged sword. J Thromb Haemost. 2022;20(4):806\u201315.","journal-title":"J Thromb Haemost"},{"key":"385_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jprot.2016.11.016","volume":"152","author":"CW Liu","year":"2017","unstructured":"Liu CW, et al. Temporal profiles of plasma proteome during childhood development. J Proteom. 2017;152:321\u20138.","journal-title":"J Proteom"},{"issue":"5","key":"385_CR40","doi-asserted-by":"crossref","first-page":"e513","DOI":"10.1212\/WNL.0000000000012233","volume":"97","author":"NM van de Velde","year":"2021","unstructured":"van de Velde NM, et al. Selection approach to identify the optimal biomarker using quantitative muscle MRI and functional assessments in Becker muscular dystrophy. Neurology. 2021;97(5):e513\u201322.","journal-title":"Neurology"}],"container-title":["Skeletal Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-025-00385-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13395-025-00385-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-025-00385-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:02:08Z","timestamp":1757714528000},"score":1,"resource":{"primary":{"URL":"https:\/\/skeletalmusclejournal.biomedcentral.com\/articles\/10.1186\/s13395-025-00385-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1186\/s13395-025-00385-3","relation":{},"ISSN":["2044-5040"],"issn-type":[{"value":"2044-5040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The affiliation of Prof. Jan G. M. Verschuuren is incorrect. His affiliation is Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed according to the Declaration of Helsinki and approved by the medical ethical committee of Leiden University Medical Center (LUMC), Leiden, The Netherlands (protocols NL50171.058.14; p05.004; p10.133) and Regionala etikpr\u00f6vningsn\u00e4mnden Stockholm, Sweden (ref. 2018\/1859-31\/1). Informed consent to participate in the study was obtained from all participants prior to the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed on the publication of the article in its current format.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}